Evidence map›Paper›PMID 30911991›Full record

Trial reportProbiotics and antimicrobial proteins2020

Bacillus coagulans Unique IS2 in Constipation: A Double-Blind, Placebo-Controlled Study.

Ratna Sudha Madempudi, Jayanthi Neelamraju, Jayesh J Ahire, Sandeep K Gupta, Vineet K Shukla

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Probiotics and antimicrobial proteins, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. [Seoul Consensus on Clinical Practice Guidelines for Functional Constipation].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2025
    Guideline
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. The Alleviative Effects ofMicroorganisms · 2025
    Article
  18. Foods (Basel, Switzerland) · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ratna Sudha MadempudiCentre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India. sudha@uniquebiotech.com.ORCID 0000-0003-1819-722X
Jayanthi NeelamrajuCentre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.
Jayesh J AhireCentre for Research and Development, Unique Biotech Ltd., Plot No. 2, Phase II, Alexandria Knowledge Park, Hyderabad, Telangana, 500078, India.
Sandeep K GuptaDepartment of Paediatrics, MV Hospital and Research Centre, First Floor, Room No. 01 314/30 Mirza Mandi Chowk, Lucknow, Uttar Pradesh, 226003, India.
Vineet K ShuklaDepartment of Paediatrics, KRM Hospital and Research Centre, First Floor, Room No. 01 3/92-93 Vijayant Khand, Lucknow, Uttar Pradesh, 226010, India.
Biotech Park · INM.V. Hospital and Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Functional constipation has a high prevalence in both adults and children affecting quality of life. Evidence suggests that probiotics can reduce the symptoms of constipation. As the effects of probiotics are strain specific, the efficacy of Bacillus coagulans Unique IS2 in the treatment of functional constipation in adults was evaluated. Subjects (n = 100) diagnosed with functional constipation were supplemented with either B. coagulans Unique IS2 (2 billion CFU) or placebo capsules once daily for 4 weeks. Subjects were evaluated for treatment success (defined as three or more spontaneous stools per week), stool consistency, difficulty of defecation, defecation and abdominal pain. By the end of the fourth week, there was a statistically significant (p < 0.001) increase in number of bowel movements in the probiotic treated group as compared to placebo. Ninety eight percent of subjects in the probiotic group achieved normal stool consistency as compared to placebo (74%). Moreover, there was relief from symptoms of incomplete evacuation, painful defecation and abdominal pain associated with constipation in probiotic treated group as compared to placebo. In conclusion, B. coagulans Unique IS2 significantly decreased the symptoms of constipation indicating effectiveness of the strain in the treatment of constipation.Trial registration: CTRI/2017/11/010539.

Indexed as

Bacillus coagulansAbdominal PainAdolescentAdultConstipationDefecationDouble-Blind MethodFecesFemaleHumansMaleMiddle AgedProbioticsQuality of LifeTreatment OutcomeYoung AdultAbdominal painB. coagulans unique IS2Bowel movementsConstipationProbiotic

Identifiers

PMID30911991
OpenAlexW2923073373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.